For Prelims: Production Linked Incentive (PLI) Scheme, Atmanirbhar Bharat, Value Chain Integration, Nodal Ministry, Scheme Name, Extension Period, Outlay, Target Segments
For Mains: Import substitution, deep manufacturing, value chain integration, Ease of Doing Business, Atmanirbhar Bharat
Source:
PIB
5 facts for one-day exams
SSC, railway, police and teaching exams ask direct questions like these.
- PLI-MD scheme extended to 2035-36.
- Fresh outlay of approximately ₹2,700 crore.
- Nodal ministry: Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals).
- Production valued at over ₹16,000 crore achieved so far.
- Scheme launched in 2020-21.
Why in the news?
The Ministry of Chemicals and Fertilizers' Production Linked Incentive Scheme for Medical Devices (PLI-MD) has been extended up to 2035-36 with a ₹2,700 crore outlay. The scheme targets deep manufacturing of high-end medical devices and critical components, with simplified eligibility and an investor-friendly framework to boost domestic production and reduce import dependence.
Summary
- PLI-MD scheme extended to 2035–36 with a fresh outlay of approximately ₹2,700 crore.
- Focus on critical component manufacturing and value chain integration for high-end devices like 3T MRI, PET-CT, and ultrasound probes.
- Minimum sales threshold to claim incentive discontinued; minimum investment requirement trimmed for Ease of Doing Business.
- Scheme has already led to domestic manufacturing of over 60 high-end medical devices and components, with production valued at over ₹16,000 crore.
Background
Launched in 2020-21, the PLI-MD scheme aimed to reduce India's dependence on imported medical devices, especially critical and high-end equipment. The first phase successfully catalysed domestic production of over 60 high-end devices, including X-ray tubes, 1.5T MRI, LINAC, CT scanners, and implants, generating production worth over ₹16,000 crore.
Key Analysis and Impact
The extension to 2035-36 with a ₹2,700 crore outlay signals long-term policy commitment. The tapering incentive rates (average ~5% for TS1, ~9% for TS2 & TS3, 6% for TS4) are designed to encourage deep manufacturing and value chain integration. Discontinuation of the minimum sales threshold and trimming of investment requirements will attract more players, especially MSMEs, and simplify compliance.
Way Forward
With continuous application window and focus on high-end devices like 3T MRI, PET-CT, and ultrasound probes, India can significantly reduce import bills, enhance self-reliance under Atmanirbhar Bharat, and improve global competitiveness. The scheme's success will depend on effective implementation and industry uptake of the simplified norms.
Background GK
Textbook concepts you need to understand this news
- Production Linked Incentive (PLI) Scheme
- A government initiative that offers financial incentives to companies for boosting domestic manufacturing and sales in specific sectors, linked to incremental production.
- Atmanirbhar Bharat
- A policy vision of the Government of India to promote self-reliance and reduce dependence on imports, especially in strategic and high-tech sectors.
- Value Chain Integration
- The process of coordinating and optimising all stages of production—from raw materials to final assembly—within a single ecosystem to improve efficiency and quality.
Facts to remember
Tap a card to see the answer. Try to recall it first.
How exams will ask this
- Data: PLI-MD scheme extended to 2035–36; outlay ₹2,700 crore; production so far ₹16,000 crore
- Nodal Body: Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals)
Don't make this mistake!
Examiners may swap the outlay of PLI-MD (₹2,700 crore) with the total production value (₹16,000 crore) or confuse it with PLI outlays for other sectors like automobiles or electronics.
Write these in mains answers
- Import substitution, deep manufacturing, value chain integration, Ease of Doing Business, Atmanirbhar Bharat
Stuck? Get it in one tap
The Production Linked Incentive Scheme for Medical Devices gives financial incentives to companies that manufacture medical devices in India. The government has extended this scheme until 2035-36 and set aside ₹2,700 crore for it. It has simplified the rules so that more companies can join, especially those making high-end equipment like MRI machines and CT scanners, which India currently imports.
- PLI-MD scheme extended to 2035-36.
- Fresh outlay of approximately ₹2,700 crore.
- Nodal ministry: Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals).
- Production valued at over ₹16,000 crore achieved so far.
- Scheme launched in 2020-21.
- Economy: Government Schemes and Incentives
- Science and Technology: Medical Technology and Devices
Related concepts: Production Linked Incentive (PLI) Scheme, Atmanirbhar Bharat, Value Chain Integration
Practice questions
Pick an answer, then read the explanation.
- Q1Easy
Which ministry is the nodal ministry for the Production Linked Incentive Scheme for Medical Devices (PLI-MD)?
Explanation: The PLI-MD scheme is administered by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers. The Ministry of Health is the end-user of medical devices but not the implementing body. Commerce and Industry handles PLI for other sectors, while Finance handles budgetary allocations.
- Q2Hard
Consider the following statements regarding the Production Linked Incentive Scheme for Medical Devices (PLI-MD):
- 1.The scheme has been extended up to 2035-36 with a fresh outlay of approximately ₹2,700 crore.
- 2.The minimum sales threshold requirement to claim incentive has been increased.
- 3.The scheme focuses on critical component manufacturing and value chain integration.
Which of the statements given above is/are correct?
Explanation: Statement 1 is correct: the scheme has been extended to 2035-36 with a ₹2,700 crore outlay. Statement 2 is incorrect: the minimum sales threshold has been discontinued, not increased. Statement 3 is correct: the scheme prioritises critical component manufacturing and value chain integration.
- Q3Medium
What is the approximate total production value that the PLI-MD scheme has achieved so far?
Explanation: The scheme has resulted in production valued at over ₹16,000 crore. ₹2,700 crore is the fresh outlay for the extended period.
- Q4Medium
What is the primary objective of extending the PLI-MD scheme with a focus on critical component manufacturing?
Explanation: The scheme aims to develop indigenous supply chains and enhance domestic manufacturing of critical components, reducing reliance on imports. It does not aim to increase imports (A). The minimum investment requirement has been trimmed, not raised (C). The scheme covers all four target segments, not just consumables (D).
Frequently asked questions
1. What is the PLI scheme for medical devices?
The Production Linked Incentive Scheme for Promoting Domestic Manufacturing of Medical Devices (PLI-MD) is a government initiative to boost domestic production of high-end medical devices and reduce import dependence.
2. Up to what year has the PLI-MD scheme been extended?
The scheme has been extended up to 2035-36.
3. What is the outlay for the extended PLI-MD scheme?
The outlay is approximately ₹2,700 crore.
4. Which ministry administers the PLI-MD scheme?
The scheme is administered by the Ministry of Chemicals and Fertilizers, through its Department of Pharmaceuticals.
All sources
- Original10 November 2026 · Read story
